Poland· PL-100534123
Gotenfia
A golimumab product containing golimumabum, registered in Poland by STADA Arzneimittel AG. The same ATC class is registered in 14 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Golimumab is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AB06 (golimumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Golimumab · ATC L04AB06
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Golimumabum
- Manufacturer
- STADA Arzneimittel AG
- Country
- Poland (PL)
- ATC code
- L04AB06
- ATC class
- Golimumab
- Defined daily dose
- 1.66 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin04011548055038
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
429 interactions on record for golimumab.
Graded by severity as the source publishes them — 287 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Golimumab · interactions on record
429 records
- 287 severe
- 135 moderate
- 7 minor
Most severe, free to view
- PrednisoloneA07EA01severe
- HydrocortisoneA07EA02severe
- PrednisoneA07EA03severe
- BetamethasoneA07EA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Golimumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaGOBIVAZADVANZ PHARMA Limited, Dublin
- IcelandGobivazADVANZ PHARMA Limited
- BelgiumGobivaz 50 mgAdvanz Pharma
- SwedenGOBIVAZ 50 mg Injektionsvätska, lösning i förfylld injektionspennaAdvanz Pharma Limited
- NorwayGobivazAdvanz Pharma Limited
- SpainGOBIVAZ 50 MG SOLUCION INYECTABLE EN PLUMA PRECARGADAAdvanz Pharma Limited
- FinlandGobivazAdvanz Pharma Limited
- SwitzerlandGobivaz 100 mg/1 ml, Injektionslösung im FertigpenAdvanz Pharma Specialty Medicine Switzerland GmbH
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Gotenfia
- Iceland · Gobivaz, Gotenfia
- Liechtenstein · Gobivaz, Gotenfia
- Norway · Gobivaz, Gotenfia
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b12d44c8-36b8-45dc-b193-ceeac4e2e62c GET /v1/drugs/b12d44c8-36b8-45dc-b193-ceeac4e2e62c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań w ampułko-strzykawce",
"source": "urpl",
"strength": "50 mg",
"packaging": "04011548055038 ¦ Rpz ¦ EU/1/25/2009/001 ¦ 166073\n1 amp.-strzyk. 0,5 ml\nRpz ¦ EU/1/25/2009/002 ¦ 166074\n3 amp.-strzyk. 0,5 ml",
"substance": "Golimumabum 50 mg",
"common_name": "Golimumabum",
"pl_product_id": "100534123",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about golimumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.